| Human chimeric antigen receptor macrophages for cancer immunotherapy M Klichinsky, M Ruella, O Shestova, XM Lu, A Best, M Zeeman, ... Nature biotechnology 38 (8), 947-953, 2020 | 858 | 2020 |
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ... The Journal of clinical investigation 126 (10), 3814-3826, 2016 | 585 | 2016 |
| GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts RM Sterner, R Sakemura, MJ Cox, N Yang, RH Khadka, CL Forsman, ... Blood, The Journal of the American Society of Hematology 133 (7), 697-709, 2019 | 513 | 2019 |
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, ... Leukemia 29 (8), 1637-1647, 2015 | 439 | 2015 |
| Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, ... Cell 173 (6), 1439-1453. e19, 2018 | 399 | 2018 |
| Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow … AJ Kansagra, NV Frey, M Bar, TW Laetsch, PA Carpenter, BN Savani, ... Biology of blood and marrow transplantation 25 (3), e76-e85, 2019 | 201* | 2019 |
| The Addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma M Ruella, SS Kenderian, O Shestova, JA Fraietta, S Qayyum, Q Zhang, ... Clinical Cancer Research 22 (11), 2684-2696, 2016 | 194 | 2016 |
| Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies EL Siegler, SS Kenderian Frontiers in immunology 11, 550628, 2020 | 188 | 2020 |
| Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells M Ruella, M Klichinsky, SS Kenderian, O Shestova, A Ziober, DO Kraft, ... Cancer discovery 7 (10), 1154-1167, 2017 | 170 | 2017 |
| Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia SK Tasian, SS Kenderian, F Shen, M Ruella, O Shestova, M Kozlowski, ... Blood, The Journal of the American Society of Hematology 129 (17), 2395-2407, 2017 | 170 | 2017 |
| Next-generation chimeric antigen receptor T-cell therapy: going off the shelf M Ruella, SS Kenderian BioDrugs 31 (6), 473-481, 2017 | 141 | 2017 |
| Treatment of cancer using anti-CD19 Chimeric Antigen Receptor CH June, DL Porter, M Maus, M Wasik, S Gill, J Fraietta, M Ruella, J Byrd, ... US Patent 10,357,514, 2019 | 127 | 2019 |
| Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis T Anagnostou, IB Riaz, SK Hashmi, MH Murad, SS Kenderian The Lancet Haematology 7 (11), e816-e826, 2020 | 113 | 2020 |
| Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms M Ruella, SS Kenderian, O Shestova, M Klichinsky, JJ Melenhorst, ... Leukemia 31 (1), 246-248, 2017 | 111 | 2017 |
| GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study Z Temesgen, M Assi, FNU Shweta, P Vergidis, SA Rizza, PR Bauer, ... Mayo Clinic Proceedings 95 (11), 2382-2394, 2020 | 105 | 2020 |
| Treatment of cancer using a CD123 chimeric antigen receptor J Brogdon, S Gill, D Glass, S Kenderian, A Loew, J Mannick, MC Milone, ... US Patent 9,815,901, 2017 | 98 | 2017 |
| Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center Y Wang, MA Tschautscher, KG Rabe, TG Call, JF Leis, SS Kenderian, ... Haematologica 105 (3), 765, 2020 | 95 | 2020 |
| Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse SS Kenderian, DL Porter, S Gill Biology of Blood and Marrow Transplantation 23 (2), 235-246, 2017 | 88 | 2017 |
| Treatment of cancer using a CLL-1 chimeric antigen receptor J Brogdon, HE Ebersbach, S Gill, D Glass, J Jascur, S Kenderian, ... US Patent 10,568,947, 2020 | 84 | 2020 |
| CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities LAK Fonkoua, O Sirpilla, R Sakemura, EL Siegler, SS Kenderian Molecular Therapy-Oncolytics 25, 69-77, 2022 | 83 | 2022 |
Marco Ruella, MDUniversity of PennsylvaniaVerified email at upenn.edu
